Drugs / Flt3L
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03789097 | Apr 2019 → Dec 2023 | breast cancer, head and neck squamous cell carcinoma, non-Hodgkin lymphoma | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Flt3L | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03789097 ↗ |
| Route | Other | “CDX-301 drug product is formulated as a sterile solution intended for single-use parenteral administration.” NCT03789097 ↗ |